{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T22:08:26Z","timestamp":1772921306635,"version":"3.50.1"},"reference-count":23,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2014,12,16]],"date-time":"2014-12-16T00:00:00Z","timestamp":1418688000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Transfusion Medicine"],"published-print":{"date-parts":[[2015,4]]},"abstract":"SUMMARY<\/jats:title>Objectives<\/jats:title>To observe and compare the clinical curative effect of the plasma exchange (PE<\/jats:styled-content>) and intravenous immunoglobulin (IVIg<\/jats:styled-content>) for Guillian\u2013Barre Syndrome (GBS<\/jats:styled-content>).<\/jats:p><\/jats:sec>Methods<\/jats:title>Overall, 64 adult patients with GBS<\/jats:styled-content> for PE<\/jats:styled-content> and IVIg<\/jats:styled-content> treatment, respectively, and nerve function were observed pre\u2010treatment and at 1\u2009week\/2\u2009weeks after completion of treatment; the blood immunoglobulin, complement, fibrinogen (Fib) and monocyte percentage (MON<\/jats:styled-content>%) were detected simultaneously.<\/jats:p><\/jats:sec>Results<\/jats:title>After PE<\/jats:styled-content> treatment, nerve function defect appeared to improve better than the IVIg<\/jats:styled-content> group and clinical effect was better than the IVIg<\/jats:styled-content> group. Treatment effective rates of the two groups after 2\u2009weeks, respectively, are 96 and 79%. PE<\/jats:styled-content> and IVIg<\/jats:styled-content> can significantly reduce the GBS<\/jats:styled-content> patients' blood immunoglobulin IgG<\/jats:styled-content>, IgA<\/jats:styled-content>, IgM<\/jats:styled-content>, C3<\/jats:styled-content> and C4<\/jats:styled-content>, but these were significantly lower in the PE<\/jats:styled-content> group than in the IVIg<\/jats:styled-content> group. Fib and MON<\/jats:styled-content>% were significantly lower in the PE<\/jats:styled-content> group than in the IVIg<\/jats:styled-content> group.<\/jats:p><\/jats:sec>Conclusion<\/jats:title>Both PE<\/jats:styled-content> and IVIg<\/jats:styled-content> have a high response as therapy and are reasonable therapeutic options for GBS<\/jats:styled-content>. However, PE<\/jats:styled-content> treatment has a more significantly curative effect, as it can effectively improve symptoms and be helpful in the early rehabilitation of patients.<\/jats:p><\/jats:sec>","DOI":"10.1111\/tme.12169","type":"journal-article","created":{"date-parts":[[2014,12,17]],"date-time":"2014-12-17T04:18:35Z","timestamp":1418789915000},"page":"79-84","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Comparison on therapeutic effect of plasma exchange and intravenous immunoglobulin for Guillian\u2013Barre syndrome"],"prefix":"10.1111","volume":"25","author":[{"given":"Y.","family":"Ye","sequence":"first","affiliation":[{"name":"Department of Blood Transfusion The Affiliated Hospital of Xi'an Medical University Xi'an Shaanxi 710077 China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.\u2010L.","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Blood Transfusion The Affiliated Hospital of Xi'an Medical University Xi'an Shaanxi 710077 China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.\u2010J.","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Neurology The Affiliated Hospital of Xi'an Medical University Xi'an Shaanxi 710077 China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2014,12,16]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410270707"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/jnr.20395"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.4103\/0972-2327.82793"},{"key":"e_1_2_6_5_1","first-page":"673","article-title":"Guidelines for the use of intravenous immunoglobulin in the treatment of neurologic diseases","volume":"51","author":"Basci\u0107\u2010Kes V.","year":"2012","journal-title":"Acta Clinica Croatica"},{"key":"e_1_2_6_6_1","first-page":"217","article-title":"Guillain\u2010Barre syndrome and IVIg: does early initiation of treatment influence the mean hospital stay?","volume":"24","author":"Coll\u2010Cant\u00ed J.","year":"2009","journal-title":"Neurolog\u00eda"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e318207b1f6"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.291.19.2367"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ncl.2013.01.005"},{"key":"e_1_2_6_10_1","first-page":"586","article-title":"Double\u2010blind trial of intravenous methylprednisolone in Guillain\u2010Barre syndrome","volume":"341","author":"Guillain\u2010Barre Syndrome Steroid Trial Group","year":"1993","journal-title":"Lancet"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(03)00264-3"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-5728(99)00195-2"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.63.6.858"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awm004"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.880141111"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra993360"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.63.7.930"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2010.09.015"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.2217\/imt.13.75"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1097\/NAN.0000000000000011"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/nau.22236"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.291.5503.484"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/jca.20071"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2013.09.002"}],"container-title":["Transfusion Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Ftme.12169","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/tme.12169","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T14:37:53Z","timestamp":1696171073000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/tme.12169"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12,16]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,4]]}},"alternative-id":["10.1111\/tme.12169"],"URL":"https:\/\/doi.org\/10.1111\/tme.12169","archive":["Portico"],"relation":{},"ISSN":["0958-7578","1365-3148"],"issn-type":[{"value":"0958-7578","type":"print"},{"value":"1365-3148","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,12,16]]},"assertion":[{"value":"2014-05-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-11-24","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-12-16","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}